HIF1A and primary cutaneous T-cell non-Hodgkin lymphoma: Vorinostat (Figure 5) is a class I/IIb/IV HDAC inhibitor, FDA approved for the treatment of cutaneous T-cell lymphoma (CTCL) and identified to be a potent inhibitor of HIF-1 signaling.